Welcome to the UPF Digital Repository

Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study

Show simple item record

dc.contributor.author Abella Monreal, Eugenia
dc.contributor.author Garcia Pallarols, Francesc
dc.contributor.author Lahsen, Randa Ben Azaiz Ben
dc.contributor.author CoronAVI@S studies
dc.date.accessioned 2023-02-06T07:33:18Z
dc.date.available 2023-02-06T07:33:18Z
dc.date.issued 2022
dc.identifier.citation Abella E, Trigueros M, Pradenas E, Muñoz-Lopez F, Garcia-Pallarols F, Ben Azaiz Ben Lahsen R, et al. Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study. Life Sci Alliance. 2022 Aug 12;5(12):e202201479. DOI: 10.26508/lsa.202201479
dc.identifier.issn 2575-1077
dc.identifier.uri http://hdl.handle.net/10230/55623
dc.description.abstract SARS-CoV-2 vaccination is the most effective strategy to protect individuals with haematologic malignancies against severe COVID-19, while eliciting limited vaccine responses. We characterized the humoral responses following 3 mo after mRNA-based vaccines in individuals at different plasma-cell disease stages: monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma on first-line therapy (MM), compared with a healthy population. Plasma samples from uninfected MM patients showed lower SARS-CoV-2-specific antibody levels and neutralization capacity compared with MGUS, SMM, and healthy individuals. Importantly, COVID-19 recovered MM individuals presented significantly higher plasma neutralization capacity compared with their uninfected counterparts, highlighting that hybrid immunity elicit stronger immunity even in this immunocompromised population. No differences in the vaccine-induced humoral responses were observed between uninfected MGUS, SMM and healthy individuals. In conclusion, MGUS and SMM patients could be SARS-CoV-2 vaccinated following the vaccine recommendations for the general population, whereas a tailored monitoring of the vaccine-induced immune responses should be considered in uninfected MM patients.
dc.description.sponsorship This work was partially funded by Grifols, the Departament de Salut of the Generalitat de Catalunya (grant DSL0016 to J Blanco and Grant DSL015 to J Carrillo), the Spanish Health Institute Carlos III (Grant PI17/01518 and PI20/00093 to J Blanco and PI18/01332 to J Carrillo), Fundació Gloria Soler, and the crowdfunding initiatives https://www.yomecorono.com, BonPreu/Esclat and Correos. M Trigueros was supported by a doctoral fellowship from the Departament de Salut from Generalitat de Catalunya (SLT017/20/000095). F Muñoz-Lopez is supported by a doctoral grant from Sorigué Foundation. E Pradenas was supported by a doctoral grant from ANID, Chile: Grant 72180406. M Massanella was granted with RYC2020-028934-I/AEI/10.13039/501100011033 from Spanish Ministry of Science and Innovation and State Research Agency, MCIN/AEI/10.13039/501100011033 and the European Social Fund “investing in your future.”
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Life Science Alliance
dc.relation.ispartof Life Sci Alliance. 2022 Aug 12;5(12):e202201479
dc.rights © 2022 Abella et al. This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).
dc.rights.uri https://creativecommons.org/licenses/by/4.0/
dc.title Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.26508/lsa.202201479
dc.relation.projectID info:eu-repo/grantAgreement/ES/2PE/RYC2020-028934-I
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


Compliant to Partaking